|
| 37503312 | Concurrent chemotherapy with partial breast irradiation in triple negative breast cancer patients may improve disease control compared with sequential therapy. | | 2023 |
| 37589839 | Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. | Breast Cancer Res Treat | 2023 |
| 37733984 | Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App. | | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 38002076 | Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions. | | 2023 |
| 36521078 | Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. | J Clin Oncol | 2023 |
| 37261654 | Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer. | | 2023 |
| 36945501 | Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. | medRxiv | 2023 |
| 34932888 | The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. | Obesity (Silver Spring) | 2022 |
| 36046124 | Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer. | Cancer Res Commun | 2022 |
| 36366886 | Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial. | Lancet | 2022 |
| 35449210 | Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. | npj Breast Cancer | 2022 |
| 35830893 | Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations. | Journal of the National Comprehensive Cancer Network : JNCCN | 2022 |
| 35439025 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 36197536 | Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer. | Breast Cancer Research and Treatment | 2022 |
| 35728015 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. | JCO Oncology Practice | 2022 |
| 35776183 | Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. | Support Care Cancer | 2022 |
| 36457510 | Automated lesion detection of breast cancer in [<sup>18</sup>F] FDG PET/CT using a novel AI-Based workflow. | Front Oncol | 2022 |
| 36657483 | The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. | | 2022 |
| 34018096 | The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote. | Journal of Cancer Survivorship | 2022 |
| 34324114 | The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures. | Annals of Surgical Oncology | 2022 |
| 35201318 | Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. | Cancer Immunol Res | 2022 |
| 35133567 | A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing. | Qual Life Res | 2022 |
| 34419350 | Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature. | Clinical Breast Cancer | 2022 |
| 34586509 | Late effects in a high-risk population of breast cancer survivors. | Supportive Care in Cancer | 2022 |
| 35074264 | Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. | Clin Breast Cancer | 2022 |
| 35330848 | Forecasting cancer: from precision to predictive medicine. | Med | 2021 |
| 34131001 | Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover). | Clin Cancer Res | 2021 |
| 33796220 | Innovating and expanding weight loss strategies for breast cancer survivors. | Oncotarget | 2021 |
| 34168046 | RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. | Clin Cancer Res | 2021 |
| 33579966 | A randomized intervention involving family to improve communication in breast cancer care. | npj Breast Cancer | 2021 |
| 33999652 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2021 |
| 34211496 | Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. | Front Genet | 2021 |
| 33512631 | Development of new brain metastases in triple negative breast cancer. | Journal of Neuro-Oncology | 2021 |
| 34096894 | Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. | Pharmacogenet Genomics | 2021 |
| 33989019 | Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2021 |
| 34135021 | Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). | Clin Cancer Res | 2021 |
| 34521857 | A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases. | npj Breast Cancer | 2021 |
| 34887491 | Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors. | npj Digital Medicine | 2021 |
| 31531802 | High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer. | Breast Cancer Res Treat | 2020 |
| 32199930 | ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). | Ann Oncol | 2020 |
| 31796517 | Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. | Clin Cancer Res | 2020 |
| 32071117 | The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial. | Clinical Cancer Research | 2020 |
| 31675252 | Reply to A. Katz. | Journal of Clinical Oncology | 2020 |
| 32110475 | Dynamic Brain Activity Following Auricular Point Acupressure in Chemotherapy-Induced Neuropathy: A Pilot Longitudinal Functional Magnetic Resonance Imaging Study. | Global Advances In Health and Medicine | 2020 |
| 32162192 | Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period. | Breast Cancer Research and Treatment | 2020 |
| 32159280 | Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): A survey of physicians from accredited breast centers in the United States. | Cancer Medicine | 2020 |
| 32158754 | Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. | Front Bioeng Biotechnol | 2020 |
| 32546323 | Management of hormone receptor-positive, HER2-negative early breast cancer. | Seminars in Oncology | 2020 |
| 32923118 | Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. | Oncoimmunology | 2020 |